Skip to main content
. 2023 Nov 20;2023(11):CD010966. doi: 10.1002/14651858.CD010966.pub4

19.5. Analysis.

19.5

Comparison 19: VX‐659 (80 mg once daily) plus tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus placebo (F508del/MF), Outcome 5: Sweat chloride (change from baseline) (mmol/L)